Redcliffe Labs is taking on incumbents like Dr Lal PathLabs. But is it biting more than it can chew?

Dheeraj Jain, founder and MD, Redcliffe Labs; image credit: Redcliffe Labs


Having set itself a target to reach INR5,000 crore in revenue by 2029, Redcliffe Labs is expanding rapidly and spending big on marketing. But scaling up in a services industry like diagnostics isn’t easy. Without sufficient funding, it may not be able to tap the small-town potential it is banking on. Besides, competition and pricing pressure are intense.

Diagnostics chain Redcliffe Labs has been making quite a buzz of late. It is gearing up to take on the incumbents and make a mark in the fragmented diagnostics market in India. Started in 2018 as a company focused genetic, specialised, and rare diseases testing, Redcliffe Labs ventured into infectious diseases, including Covid-19 testing in 2020 and expanded to a full-stack testing menu of routine and specialised pathology tests as well as

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *